FR 180204
Based on 26 publication(s) in Google Scholar
FR 180204 is an ATP-competitive and selective ERK inhibitor. FR 180204 inhibits ERK1 and ERK2 with IC50s of 0.51 μM (Ki=0.31 μM) and 0.33 μM (Ki=0.14 μM), respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.91%
- No. CAS: 865362-74-9
- Fòrmula: C18H13N7
- Peso molecular:327.34
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) FR 180204
More- Immunity. 2022 Dec 13;55(12):2285-2299.e7. [Abstract]
- Autophagy. 2026 Apr 23:1-26. [Abstract]
- Neuron. 2025 Nov 18:S0896-6273(25)00803-7. [Abstract]
- Adv Sci (Weinh). 2025 Sep 26:e02395. [Abstract]
- Cell Death Differ. 2019 Mar;26(3):426-442. [Abstract]
- J Transl Med. 2021 Dec 7;19(1):497. [Abstract]
- Int J Biol Macromol. 2025 Feb 11:140937. [Abstract]
- Antioxidants (Basel). 2024 Jul 11;13(7):831. [Abstract]
- Cell Mol Life Sci. 2024 Jul 30;81(1):325. [Abstract]
- Inflammation. 2018 Jun;41(3):751-759. [Abstract]
- Cell Signal. 2026 Jun:142:112431. [Abstract]
- Cell Signal. 2025 Jul:131:111706. [Abstract]
- J Pharmacol Exp Ther. 2020 Jul;374(1):104-112. [Abstract]
- Mater Technol (N Y N Y). 2025 Jun 17.
- Vet Res. 2023 Nov 15;54(1):106. [Abstract]
- Am J Cancer Res. 2022 Jul 15;12(7):3405-3421. [Abstract]
- Microbes Infect. 2025 Feb;27(2):105428. [Abstract]
- Vet Microbiol. 2025 Dec 29:313:110858. [Abstract]
- J Cardiovasc Transl Res. 2020 Apr;13(2):215-224. [Abstract]
- Onco Targets Ther. 2021 Oct 22;14:5131-5144. [Abstract]
- Research Square Preprint. 2023 Apr 10.
- Research Square Print. 2023 Feb 1.
- Biomed Pharmacother. 2022 Sep:153:113502. [Abstract]
- Research Square Preprint. 2021 Nov.
- Environ Toxicol. 2021 Feb;36(2):276-286. [Abstract]
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
-
WB
-
WB
Actividad biológica
|
ERK2 0.14 μM (Ki) |
ERK1 0.31 μM (Ki) |
ERK2 0.33 μM (IC50) |
ERK1 0.51 μM (IC50) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 865362-74-9
-
Appearance Solid
-
Peso molecular 327.34
-
Fòrmula C18H13N7
-
Color Light yellow to yellow
-
SMILES
NC1=NNC2=NN=C(C3=C4C=CC=CN4N=C3C5=CC=CC=C5)C=C21
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Neutrophil "plucking" on megakaryocytes drives platelet production and boosts cardiovascular disease. [Abstract]2022 Dec 13;55(12):2285-2299.e7. PMID: 36272416 -
Autophagy
PBK-Loaded secretory autophagosomes drive radiotherapy-induced systemic adipose depletion via MAPK/ERK-PRKA/PKA-LIPE/HSL signaling: a therapeutic target for esophageal cancer cachexia. [Abstract]2026 Apr 23:1-26. PMID: 41988986 -
Neuron
2025 Nov 18:S0896-6273(25)00803-7. PMID: 41260217 -
Adv Sci (Weinh)
Calhm6 Governs Macrophage Polarization Through Chp1-Camk4-Creb1 Axis and Ectosomal Delivery in Inflammatory Responses. [Abstract]2025 Sep 26:e02395. PMID: 40999918 -
Cell Death Differ
c-Myc inhibits myoblast differentiation and promotes myoblast proliferation and muscle fibre hypertrophy by regulating the expression of its target genes, miRNAs and lincRNAs. [Abstract]2019 Mar;26(3):426-442. PMID: 29786076
FR 180204 purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2019 Mar;26(3):426-442. [Abstract]
Chicken breast muscles are injected with FR180204 or control, and the protein levels of the ERK1 and p-ERK are analysed.
-
J Transl Med
Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis. [Abstract]2021 Dec 7;19(1):497. PMID: 34876143 -
Int J Biol Macromol
Ginsenoside Rb1 inhibits porcine epidemic diarrhea virus replication through suppressing S1 protein mediated the MAPK/ERK pathway and reducing apoptosis. [Abstract]2025 Feb 11:140937. PMID: 39947549 -
Antioxidants (Basel)
Canagliflozin Inhibits Palmitic Acid-Induced Vascular Cell Aging In Vitro through ROS/ERK and Ferroptosis Pathways. [Abstract]2024 Jul 11;13(7):831. PMID: 39061899 -
Cell Mol Life Sci
Suppression of Skp2 contributes to sepsis-induced acute lung injury by enhancing ferroptosis through the ubiquitination of SLC3A2. [Abstract]2024 Jul 30;81(1):325. PMID: 39079969 -
Inflammation
2018 Jun;41(3):751-759. PMID: 29427162
FR 180204 purchased from MedChemExpress. Usage Cited in: Inflammation. 2018 Jun;41(3):751-759. [Abstract]
ERK1/2-specific inhibitor (FR 180204) is responsible for the inhibition of FGF21-induced IL-10 expression without affecting the viability of the THP-1 cells.
-
Cell Signal
A novel role of follicular fluid chemokine CCL21 in promoting porcine oocyte in vitro maturation through activating ERK1/2 signaling pathway. [Abstract]2026 Jun:142:112431. PMID: 41720327 -
Cell Signal
Paeoniflorin-6'-O-benzene sulfonate inhibits keratinocyte proliferation by restoring GRK2-JAK1 colocalization in mouse model of psoriasis. [Abstract]2025 Jul:131:111706. PMID: 40037425 -
J Pharmacol Exp Ther
2020 Jul;374(1):104-112. PMID: 32434944 -
-
Vet Res
The CD2v protein of African swine fever virus inhibits macrophage migration and inflammatory cytokines expression by downregulating EGR1 expression through dampening ERK1/2 activity. [Abstract]2023 Nov 15;54(1):106. PMID: 37968713 -
Am J Cancer Res
2022 Jul 15;12(7):3405-3421. PMID: 35968337 -
Microbes Infect
Suppressive effects of toll-like receptor 2, toll-like receptor 4, and toll-like receptor 7 on protective responses to Mycobacterium bovis BCG from epithelial cells. [Abstract]2025 Feb;27(2):105428. PMID: 39368609 -
Vet Microbiol
AS-IV exhibits anti-SADS-CoV effects through the inhibition of the MAPK/JNK signaling pathway mediated by the S1 protein. [Abstract]2025 Dec 29:313:110858. PMID: 41477941 -
J Cardiovasc Transl Res
Foam Cell-Derived CXCL14 Muti-Functionally Promotes Atherogenesis and Is a Potent Therapeutic Target in Atherosclerosis. [Abstract]2020 Apr;13(2):215-224. PMID: 31728901 -
Onco Targets Ther
18β-Glycyrrhetinic Acid Has Anti-Cancer Effects via Inducing Apoptosis and G2/M Cell Cycle Arrest, and Inhibiting Migration of A549 Lung Cancer Cells. [Abstract]2021 Oct 22;14:5131-5144. PMID: 34712051 -
-
-
Biomed Pharmacother
NT157 inhibits cell proliferation and sensitizes glioma cells to TRAIL-induced apoptosis by up-regulating DR5 expression. [Abstract]2022 Sep:153:113502. PMID: 36076591 -
-
Environ Toxicol
Molecular mechanisms of quinalizarin induces apoptosis and G0/G1 cell cycle of human esophageal cancer HCE-4 cells depends on MAPK, STAT3, and NF-κB signaling pathways. [Abstract]2021 Feb;36(2):276-286. PMID: 33030807 -
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077
Solvente y solubilidad
DMSO : ≥ 50 mg/mL (152.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
Nunc-Immuno MaxiSorp plates are coated with 20 μg/mL MBP solution in phosphate-buffered saline (PBS). After washing with PBS containing 0.05% Tween 20 (T-PBS), blocking buffer (T-PBS containing 3% BSA) is added to each well and the plates are incubated for 10 min at room temperature. After washing with T-PBS, chemical compounds, ATP and recombinant ERK2 diluted in assay dilution buffer (20 mM Mops, pH 7.2, 25 mM β-glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, and 50 μg/mL BSA) and are added to each well. Vehicle groups (containing 0.1% DMSO) and kinase-withdrawal groups are used for the control and basal determinations. After incubation for 1 h at room temperature, plates are washed twice with T-PBS. Anti-phospho MBP antibody (0.2 μg/mL) is added to each well, and the plates are incubated for 1 h at room temperature. After washing, anti-mouse HRP-conjugated polyclonal antibodies are added and the plates are incubated for 30 min.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In brief, mice are randomized and grouped by body weight immediately before treatment. Bovine CII is dissolved in 0.1mol/Lacetic acid at the concentration of 10 mg/mL and then emulsified in an equal volume of Freund’s complete adjuvant H37Rv. Apart from a naive group, each mouse is immunized with 25 μL of the CII emulsion into the tail base, followed by a boost injection 3 weeks after primary injection (day 0). FR180204 and methylprednisolone are ground and suspended in 0.1% methylcellulose solution to a volume of 5 mL/kg. Drugs are given by twice daily intraperitoneal injection from days 0 to 12 in accordance with pharmacokinetic studies with superior area under the curve and Cmax values of i.p. versus s.c. or p.o. administration. The initial administration is 30 min before the boost CII injection. The clinical score of arthritis is obtained by summing the visual severity grade of each limb, scored as follows: 0, no arthritis; 1, one swollen digit; 2, two or more swollen digits or swelling of the entire paw without ankylosis; 3, gross swelling with ankylosis of the paw. Body weight is measured on day 12.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (287 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Ohori M, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun. 2005 Oct 14;336(1):357-63. [Content Brief]
[2]. Ohori M, et al. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2007 Jan;374(4):311-6. [Content Brief]
[3]. Honda M, et al. Mesothelioma cell proliferation through autocrine activation of PDGF-ββ receptor. Cell Physiol Biochem. 2012;29(5-6):667-74 [Content Brief]
[4]. Sreekanth GP, et al. Role of ERK1/2 signaling in dengue virus-induced liver injury. Virus Res. 2014 Aug 8;188:15-26 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0549 mL | 15.2746 mL | 30.5493 mL | 76.3732 mL |
| 5 mM | 0.6110 mL | 3.0549 mL | 6.1099 mL | 15.2746 mL | |
| 10 mM | 0.3055 mL | 1.5275 mL | 3.0549 mL | 7.6373 mL | |
| 15 mM | 0.2037 mL | 1.0183 mL | 2.0366 mL | 5.0915 mL | |
| 20 mM | 0.1527 mL | 0.7637 mL | 1.5275 mL | 3.8187 mL | |
| 25 mM | 0.1222 mL | 0.6110 mL | 1.2220 mL | 3.0549 mL | |
| 30 mM | 0.1018 mL | 0.5092 mL | 1.0183 mL | 2.5458 mL | |
| 40 mM | 0.0764 mL | 0.3819 mL | 0.7637 mL | 1.9093 mL | |
| 50 mM | 0.0611 mL | 0.3055 mL | 0.6110 mL | 1.5275 mL | |
| 60 mM | 0.0509 mL | 0.2546 mL | 0.5092 mL | 1.2729 mL | |
| 80 mM | 0.0382 mL | 0.1909 mL | 0.3819 mL | 0.9547 mL | |
| 100 mM | 0.0305 mL | 0.1527 mL | 0.3055 mL | 0.7637 mL |